IP Verse

Formulations Of Enzalutamide - EP3725778

The patent EP3725778 was granted to Astellas Pharma on Aug 18, 2021. The application was originally filed on Sep 11, 2013 under application number EP20177837A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3725778

ASTELLAS PHARMA
Application Number
EP20177837A
Filing Date
Sep 11, 2013
Status
Granted And Under Opposition
Jul 16, 2021
Grant Date
Aug 18, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (11)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ACCORD HEALTHCAREMay 18, 2022TER MEER STEINMEISTER & PARTNERADMISSIBLE
ALFRED E TIEFENBACHERMay 18, 2022HAMM & WITTKOPPADMISSIBLE
BULLE DRMay 18, 2022KUTZENBERGER WOLFF & PARTNERADMISSIBLE
ELKINGTON AND FIFEMay 18, 2022ELKINGTON AND FIFEADMISSIBLE
HAMM & WITTKOPPMay 18, 2022HAMM & WITTKOPPADMISSIBLE
MAIWALDMay 18, 2022MAIWALDADMISSIBLE
STADA ARZNEIMITTELMay 18, 2022HAMM & WITTKOPPADMISSIBLE
SYNTHONMay 18, 2022HAMM & WITTKOPPADMISSIBLE
DR SCHONMay 17, 2022DR SCHONADMISSIBLE
ZENTIVA KSMay 13, 2022REDDIE & GROSEADMISSIBLE
SANDOZMay 11, 2022MAIWALDADMISSIBLE

Patent Citations (24) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2002009494
DESCRIPTIONUS2002031547
DESCRIPTIONUS7611630
DESCRIPTIONUS7709517
OPPOSITIONEP0901786
OPPOSITIONEP1741424
OPPOSITIONEP1893196
OPPOSITIONEP3725778
OPPOSITIONUS2002009494
OPPOSITIONUS2007004753
OPPOSITIONWO02067893
OPPOSITIONWO03032950
OPPOSITIONWO03043606
OPPOSITIONWO03063821
OPPOSITIONWO2010114928
OPPOSITIONWO2014043208
OTHEREP1741424
OTHERUS2007004753
OTHERUS7709517
OTHERWO03063821
OTHERWO2014043208
SEARCHUS2007004753
SEARCHUS7709517
SEARCHWO03063821

Non-Patent Literature (NPL) Citations (71) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- MARSHALL, "Atomization and Spray-Drying", Chem. Eng. Prog. Monogr., (19540000), vol. 50-
DESCRIPTION- PERRY'S, Chemical Engineers' Handbook, McGraw-Hill Book Co., (19840000), pages 20 54 - 20 57-
OPPOSITION- Anonymous, "A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects", Clinical Trials Protocol NCT01911741, (20130730), Clinical Trials Protocol NCT01911741, URL: https://clinicaltrials.gov/ct2/show/NCT01911741, (20220530), XP055925759-
OPPOSITION- Anonymous, "BIOAVAILABILITY ENHANCEMENT - Addressing Solubility Challenges: Using Effective Technology & Problem-Solving for Delivery Solutions", DRUG DEVELOPMENT AND DELIVERY, (20120701), DRUG DEVELOPMENT AND DELIVERY , (20220531), XP055926313-
OPPOSITION- Anonymous, "CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 20315Orig1s000 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEWS(S) - Reference ID:3175035", FDA Clinical Pharmacology Review XTANDI, (20120722), pages 1 - 83, XP055926491-
OPPOSITION- Anonymous, "Highlighs of Prescribing Information for XTANDI", FDA, (20120801), FDA, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203415lbl.pdf, (20200316), XP055676626-
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION for XTANDI", Prescribing Information, (20120801), pages 1 - 16, XP055926948-
OPPOSITION- Anonymous, "Immediate-Release Drug Delivery Systems I : Increasing the solubility and dissolution rate of drugs; pages", Anonymous, Yvonne Perrie , Thomas Rades, Pharmaceutics: Drug Delivery and Targeting Second Edition , Pharmaceutical Press, (20120101), pages 37 - 50, ISBN 978-0-85369-762-6, XP093156316-
OPPOSITION- Anonymous, "Partition Coefficients", Anonymous, James Swarbrick , James C Boylan, Encyclopaedia of Pharmaceutical Technology, Vol. 11, United States of America, Marcel Dekker INC, (19950101), pages 293 - 306, ISBN 978-0-8247-2810-6, XP093156330-
OPPOSITION- Anonymous, "PRODUCT INFORMATION XTANDI ® (enzalutamide) capsues for oral use", Xtandi, (20120000), pages 1 - 16, XP055926485-
OPPOSITION- Anonymous, "The Presidential Green Chemistry Challenge Awards Program: Summary of 2010 Award Entries and Recipients", EPA UNITED STATES ENVIRONMENTAL PROTECTION AGENCY, (20100601), EPA UNITED STATES ENVIRONMENTAL PROTECTION AGENCY, (20220531), XP055926312-
OPPOSITION- AULTON, M.E, PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN, 2nd ed., (20020000), page 241, XP055466214-
OPPOSITION- Bellantone R., "1.9 Summary and Closing Remarks", Amorphous Solid Dispersions. Advances in Delivery Science and Technology, Springer, New York, (20141122), page 33, ISBN 978-1-4939-1597-2, XP093175991-
OPPOSITION- BEND RESEARCH, "Spray Drying of Amorphous Dispersions", Pharmaceutical Technology Europe, (20120902), vol. 24, no. 9, pages 1 - 2, XP055925641-
OPPOSITION- Bevernage J., Forier T., Brouwers J., Tack J., Annaert P., Augustijns P., "Excipient Mediated Supersaturation Stabilization in Human Intestinal Fluids", Molecular Pharmaceutics, (20110126), vol. 8, no. 2, pages 564 - 570, XP055926970-
OPPOSITION- Calahan Julie L, "Characterization of Amorphous Solid Dispersions of AMG 517 in HPMC-AS and Crystallization using Isothermal Microcalorimetry", Thesis, University of Kansas, University of Kansas, (20110411), Thesis, URL: https://kuscholarworks.ku.edu/bitstream/handle/1808/7647/Calahan_ku_0099M_11487_DATA_1.pdf?sequence=1, (20220530), XP055925630-
OPPOSITION- CENTER FOR DRUG EVALUATION AND RESEARCH, "XTANDI â„¢ - Enzalutamide", Clinical Pharmacology and Biopharmaceutics Review(s), (20120522), XP055925638-
OPPOSITION- Center Of Drug Evaluation & Research, "NDA 20.3415 Review - Enzalutamide", CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S), (20120801), pages 1 - 70, CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S), (20220525), XP055924997-
OPPOSITION- Fda, "XTANDI ® (enzalutamide) capsules for oral use", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20120101), pages 1 - 16, HIGHLIGHTS OF PRESCRIBING INFORMATION, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203415lbl.pdf, (20220530), XP055925642-
OPPOSITION- Fda, "XTANDI ® (enzalutamide) capsules for oral use", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20120801), pages 1 - 16, HIGHLIGHTS OF PRESCRIBING INFORMATION, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203415lbl.pdf, (20220530), XP055925642-
OPPOSITION- Gao Ping, "Amorphous Pharmaceutical Solids: Characterization, Stabilization, and Development of Marketable Formulations of Poorly Soluble Drugs with Improved Oral Absorption", Molecular Pharmaceutics, (20080101), vol. 5, no. 6, pages 903 - 904, XP055924986-
OPPOSITION- "Kapitel 9", Die Tablette, page 582, XP055925753-
OPPOSITION- KONNO et al., "Ability of Different Polymers to Inhibit the Crystallization of Amorphous Felodipine in the Presence of Moisture", Pharmaceutical Research, (20080000), vol. 25, no. 4, pages 969 - 978, XP019613023-
OPPOSITION- Lynnes Taylor, "Probing the Precipitation Behavior of Poorly Water Soluble Compounds", AAPS 2017, Purdue University, Purdue University , (20170711), pages 1 - 43, AAPS 2017, URL: https://zerista.s3.amazonaws.com/item_files/edaf/attachments/413306/original/75_91.pdf, (20201203), XP055756223-
OPPOSITION- Machado P., Kite J., "U.S. FDA Approves XTANDI® (enzalutamide) After Priority Review for Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated with Docetaxel", MEDIVATION - Press release, (20120831), XP055925756-
OPPOSITION- Michael E. Aulton, Et Al., "Bioavailability - physicochemical and dosage form factors", PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN, Second Edition, Elsevier , (20020101), pages 234 - 252, ISBN 0-443-05517-3, XP055466214-
OPPOSITION- Mike Reading , Duncan Q M Craig, "Principles of Differential Scanning Calorimetry", Mike Reading , Duncan Q M Craig, Duncan Q M Craig , Mike Reading, Thermal analysis of Pharmaceuticals , CRC Press , (20070101), pages 1 - 20, ISBN 978-0-8247-5814-1, XP093156335-
OPPOSITION- Ritschel W. A., Bauer-Brandl A., "Kapitel 9", Ritschel W. A., Bauer-Brandl A., Ritschel W A; Bauer-Brandl A, Die Tablette, Cantor Verlag, (20110101), page 582, ISBN 978-3-87193-407-0, XP055925753-
OPPOSITION- Rowe R. C., "Hypromellose Acetate Succinate", Handbook of Pharmaceutical Excipients. 6th Ed., PhP, (20120101), pages 377 - 380, XP055925757-
OPPOSITION- David T. Vodak, Michael Morgen, "Design and Development of HPMCAS-Based Spray-Dried Dispersions", Advances in Delivery Science and Technology, (20140101), pages 303 - 322, doi:10.1007/978-1-4939-1598-9_9, ISSN 2192-6204, XP055556625
OPPOSITION- CURATOLO et al., "Hydroxypropylmethylcellulose Acetate Succinate (HPMCAS) for Initiation and Maintenance of Drug Supersaturation in the GI Milieu", Pharmaceutical Research, (20090000), vol. 26, no. 6, pages 1419 - 1431, XP019686188
OPPOSITION- Curatolo et al., "Utility of Hydroxypropylmethylcellulose Acetate Succinate (HPMCAS) for Initiation and Maintenance of Drug Supersaturation in the GI Milieu", PHARMACEUTICAL RESEARCH, NL , (20090310), vol. 26, no. 6, doi:10.1007/s11095-009-9852-z, ISSN 1573-904X, pages 1419 - 1431, XP019686188
OPPOSITION- William Curatolo ; James A. Nightingale ; Scott M. Herbig, "Utility of Hydroxypropylmethylcellulose Acetate Succinate (HPMCAS) for Initiation and Maintenance of Drug Supersaturation in the GI Milieu", PHARMACEUTICAL RESEARCH, Kluwer Academic Publishers-Plenum Publishers, NL, NL , (20090310), vol. 26, no. 6, doi:10.1007/s11095-009-9852-z, ISSN 1573-904X, pages 1419 - 1431, XP019686188
OPPOSITION- Alfred C. F. Rumondor ; Lindsay A. Stanford ; Lynne S. Taylor, "Effects of Polymer Type and Storage Relative Humidity on the Kinetics of Felodipine Crystallization from Amorphous Solid Dispersions", PHARMACEUTICAL RESEARCH, Kluwer Academic Publishers-Plenum Publishers, NL, NL , (20091006), vol. 26, no. 12, doi:10.1007/s11095-009-9974-3, ISSN 1573-904X, pages 2599 - 2606, XP019752644
OPPOSITION- Konno et al., "Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, NL , (20081001), vol. 70, no. 2, doi:10.1016/j.ejpb.2008.05.023, ISSN 0939-6411, pages 493 - 499, XP025470891
OPPOSITION- Konno Hajime, Handa Tetsurou, Alonzo David E., Taylor Lynne S., "Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine", Eu. J. PHarm. Biopharm., (20080000), vol. 70, pages 493 - 499, XP025470891
OPPOSITION- Konno, H. ; Handa, T. ; Alonzo, D.E. ; Taylor, L.S., "Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM., NL, NL , (20081001), vol. 70, no. 2, doi:10.1016/j.ejpb.2008.05.023, ISSN 0939-6411, pages 493 - 499, XP025470891
OPPOSITION- Zecevic Damir Elmar; Meier Robin; Daniels Rolf; Wagner Karl-Gerhard, "Site specific solubility improvement using solid dispersions of HPMC-AS/HPC SSL - Mixt", European journal of pharmaceutics and biopharmaceutics, NL , (20140421), vol. 87, no. 2, doi:10.1016/j.ejpb.2014.03.018, ISSN 0939-6411, pages 264 - 270, XP028865991
OPPOSITION- Indrajit Ghosh; Jennifer Snyder; Radha Vippagunta; Marilyn Alvine; Ronak Vakil; Wei-Qin (Tony) Tong; Sudha Vippagunta;, "Comparison of HPMC based polymers performance as carriers for manufacture of solid dispersions using the melt extruder", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, NL , (20110526), vol. 419, no. 1, doi:10.1016/j.ijpharm.2011.05.073, ISSN 0378-5173, pages 12 - 19, XP028306607
OPPOSITION- Jørgensen Jacob Rune, Mohr Wolfgang; Rischer Matthias; Sauer Andreas; Mistry Shilpa; Müllertz Anette; Rades Thomas, "Stability and intrinsic dissolution of vacuum compression molded amorphous solid dispersions of efavirenz", International Journal of Pharmaceutics, ELSEVIER, NL, NL , (20230201), vol. 632, doi:10.1016/j.ijpharm.2022.122564, ISSN 0378-5173, page 122564, XP093175978
OPPOSITION- Venecia Wilson, Xiaochun Lou, Donald J. Osterling, Deanne F. Stolarik, Gary Jenkins, Wenqing Gao, Geoff G.Z. Zhang, Lynne S. Taylor, "Relationship between amorphous solid dispersion in vivo absorption and in vitro dissolution: phase behavior during dissolution, speciation, and membrane mass transport", Journal of Controlled Release, AMSTERDAM, NL , (20181201), vol. 292, doi:10.1016/j.jconrel.2018.11.003, ISSN 0168-3659, pages 172 - 182, XP055748090
OPPOSITION- Yingqing Ran , Samuel H. Yalkowsky, "Prediction of Drug Solubility by the General Solubility Equation (GSE)", Journal of chemical information and computer sciences, US , (20010301), vol. 41, no. 2, doi:10.1021/ci000338c, ISSN 0095-2338, pages 354 - 357, XP093156322
OPPOSITION- Miller Jonathan M., Beig Avital, Carr Robert A., Spence Julie K., Dahan Arik, "A Win-Win Solution in Oral Delivery of Lipophilic Drugs: Supersaturation via Amorphous Solid Dispersions Increases Apparent Solubility without Sacrifice of Intestinal Membrane Permeability", Molecular Pharmaceutics, American Chemical Society, US, US , (20120702), vol. 9, no. 7, doi:10.1021/mp300104s, ISSN 1543-8384, pages 2009 - 2016, XP055812634
OPPOSITION- D.T. FRIESEN et al., "Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray- Dried Dispersions: An Overview", Molecular Pharmaceutics, (20081201), vol. 5, no. 6, doi:10.1021/mp8000793, pages 1003 - 1019, XP055056966
OPPOSITION- Dwayne T. Friesen, Ravi Shanker, Marshall Crew, Daniel T. Smithey, W. J. Curatolo, J. A. S. Nightingale, "Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview", Molecular Pharmaceutics, American Chemical Society, (20081201), vol. 5, no. 6, doi:10.1021/mp8000793, ISSN 15438384, pages 1003 - 1019, XP055056966
OPPOSITION- Friesen Dwayne T., Shanker Ravi, Crew Marshall, Smithey Daniel T., Curatolo W. J., Nightingale J. A. S., "Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview", Molecular Pharmaceutics, (20080000), vol. 5, no. 6, pages 1003 - 1019, XP055056966
OPPOSITION- FRIESEN et al., "Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview", Molecular Pharmaceutics, (20080000), vol. 5, no. 6, doi:10.1021/mp8000793, XP055056966
OPPOSITION- Friesen et al., "Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview", Molecular Pharmaceutics, (20081201), vol. 5, no. 6, doi:10.1021/mp8000793, ISSN 15438384, pages 1003 - 1019, XP055056966
OPPOSITION- Scher Howard I., Fizazi Karim, Saad Fred, Taplin Mary-Ellen, Sternberg Cora N., Miller Kurt, De Wit Ronald, Mulders Peter, Chi Kim N., Shore Neal D., Armstrong Andrew J., Flaig Thomas W., Fléchon Aude, Mainwaring Paul, Fleming Mark, Hainsworth John D., Hirmand Mohammad, Selby Bryan, Seely Lynn, De Bono Johann S., "Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy", The New England journal of medicine, Massachusetts Medical Society, US, US , (20120927), vol. 367, no. 13, doi:10.1056/NEJMoa1207506, ISSN 0028-4793, pages 1187 - 1197, XP055925762
OPPOSITION- R. SAVLA et al., "Review and analysis of FDA approved drugs using lipid-based formula- tions", Drug Development and Industrial Pharmacy, (20170706), vol. 43, no. 11, pages 1743 - 1758, XP055926311
OPPOSITION- Tanno Fumié; Nishiyama Yuichi; Kokubo Hiroyasu; Obara Sakaé, "Evaluation of hypromellose acetate succinate (HPMCAS) as a carrier in solid dispersions.", Journal Drug Development and Industrial Pharmacy, NEW YORK, NY, US, US , (20040101), vol. 30, no. 1, doi:10.1081/DDC-120027506, ISSN 0363-9045, pages 9 - 17, XP009124621
OPPOSITION- Ping Gao; Yi Shi, "Characterization of Supersaturatable Formulations for Improved Absorption of Poorly Soluble Drugs", AAPS JOURNAL, AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS, US, US , (20120714), vol. 14, no. 4, doi:10.1208/s12248-012-9389-7, ISSN 1550-7416, pages 703 - 713, XP035127455
OPPOSITION- ZEDONG DONG; DUK SOON CHOI, "Hydroxypropyl Methylcellulose Acetate Succinate: Potential Drug-Excipient Incompatibility", AAPS PharmSciTech, (20080900), vol. 9, no. 3, pages 991 - 997, XP001562286
OPPOSITION- Monschke Marius; Kayser Kevin; Wagner Karl G., "Influence of Particle Size and Drug Load on Amorphous Solid Dispersions Containing pH-Dependent Soluble Polymers and the Weak Base Ketoconazole", AAPS PharmSciTech, Springer International Publishing, Cham, Cham , (19000101), vol. 22, no. 1, doi:10.1208/s12249-020-01914-7, XP037334137
OPPOSITION- James C. Dinunzio, Justin R. Hughey, Chris Brough, Dave A. Miller, Robert O. Williams Iii, James W. Mcginity, "Production of advanced solid dispersions for enhanced bioavailability of itraconazole using KinetiSol® Dispersing", Drug Development and Industrial Pharmacy, (20100901), vol. 36, no. 9, doi:10.3109/03639041003652973, ISSN 03639045, pages 1064 - 1078, XP055172122
OPPOSITION- Hugo Marc, Kunath Klaus, Dressman Jennifer, "Selection of excipient, solvent and packaging to optimize the performance of spray-dried formulations: case example fenofibrate", Journal Drug Development and Industrial Pharmacy, NEW YORK, NY, US, US , (20130201), vol. 39, no. 2, doi:10.3109/03639045.2012.685176, ISSN 0363-9045, pages 402 - 412, XP093164754
OPPOSITION- Dallas B. Warren, Benameur Hassan, Porter Christopher J.H., Pouton Colin W., "Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility", Journal of Drug Targeting, (20101201), vol. 18, no. 10, doi:10.3109/1061186X.2010.525652, ISSN 1061186X, pages 704 - 731, XP055027752
OPPOSITION- Dallas B. Warren, "Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility", Journal of Drug Targeting, (20101201), vol. 18, no. 10, doi:10.3109/1061186X.2010.525652, ISSN 1061-186x, pages 704 - 731, XP008152135
OPPOSITION- WARREN, D.B. et al., "Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility", Journal of Drug Targeting, (20100000), vol. 18, no. 10, doi:10.3109/1061186X.2010.525652, pages 704 - 731, XP055027752
OPPOSITION- Monschke Marius, Wagner Karl G., "Impact of HPMCAS on the Dissolution Performance of Polyvinyl Alcohol Celecoxib Amorphous Solid Dispersions", Pharmaceutics, MDPI AG, Switzerland, Switzerland, (20200611), vol. 12, no. 6, doi:10.3390/pharmaceutics12060541, ISSN 1999-4923, page 541, XP093175979
OPPOSITION- Srushti Tambe, "Recent Advances in Amorphous Solid Dispersions: Preformulation, Formulation Strategies, Technological Advancements and Characterization", Pharmaceutics, CH , (20221016), vol. 14, no. 10, doi:10.3390/pharmaceutics14102203, ISSN 1999-4923, pages 1 - 33, XP093156308
OTHER- Anonymous, "Highlighs of Prescribing Information for XTANDI", FDA, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203415lbl.pdf, XP055676626-
OTHER- Lynne S. Taylor, "Probing the Precipitation Behavior of Poorly Water Soluble Compounds", AAPS 2017, Purdue University, (20170711), pages 1 - 43, URL: https://zerista.s3.amazonaws.com/item_files/edaf/attachments/413306/original/75_91.pdf, XP055756223-
OTHER- W. CURATOLO et al., "Utility of Hydroxypropylmethylcellulose Acetate Succinate (HPMCAS) for Initiation and Maintenance of Drug Supersaturation in the GI Milieu", Pharmaceut. Res., (20090310), vol. 26, no. 6, pages 1419 - 1431, XP019686188
OTHER- H. KONNO et al., "Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine", Eu. J. Pharm. Biopharm., (20081000), vol. 70, no. 2, pages 493 - 499, XP025470891
OTHER- D.T. FRIESEN et al., "Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview", Molec. Pharmaceut., (20081200), vol. 5, no. 6, pages 1003 - 1019, XP055056966
OTHER- DT FRIESEN et al., "Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview", Molecular Pharmaceutics, (20081201), vol. 5, no. 6, pages 1003 - 1019, XP055056966
OTHER- F. TANNO et al., "009124621 Evaluation of hypromellose acetate succinate (HPMCAS) as a carrier in solid dispersions", Drug Developm. Ind. Pharm., (20040101), vol. 30, no. 1, pages 9 - 17, XP009124621
OTHER- D.B. WARREN et al., "Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility", J. Drug. Target., (20101201), vol. 18, no. 10, pages 704 - 731, XP008152135
SEARCH- Anonymous, "Prescribing Information for XTANDI", (20120801), URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203415lbl.pdf, (20200316), XP055676626 [A] 1-20 * the whole document * * par. 1-3 of the "Full Prescribing Information" *-
SEARCH- DWAYNE T. FRIESEN ET AL, "Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview", MOLECULAR PHARMACEUTICS, (20081201), vol. 5, no. 6, doi:10.1021/mp8000793, ISSN 1543-8384, pages 1003 - 1019, XP055056966 [A] 1-20 * the whole document * * Experimental Section * * table 1 * * abstract *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents